Skip to main content
Top
Published in: Rheumatology International 5/2011

01-05-2011 | Original Article

Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis

Authors: Kumi Shidara, Eisuke Inoue, Eiichi Tanaka, Daisuke Hoshi, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi, Hisashi Yamanaka

Published in: Rheumatology International | Issue 5/2011

Login to get access

Abstract

The anti-cyclic citrullinated peptide (CCP) antibody has become increasingly important in the diagnosis of rheumatoid arthritis (RA), especially for early diagnosis. The purpose of this study is to compare the diagnostic usefulness of the second and third generation anti-CCP antibody kits among Japanese patients with RA. Anti-CCP antibody titers were measured with the second generation (MESACUP CCP test, Medical and biological laboratories) and third generation (QUANTA Lite CCP3 IgG ELISA, Inova Diagnostics) kits using serum samples from 106 rheumatoid arthritis (RA) patients and 57 non-RA patients. Sensitivities and specificities were compared. The sensitivity and specificity of the second generation anti-CCP (anti-CCP2) kit were 88.7 and 89.5%, and those of the third generation anti-CCP (anti-CCP3) kit were 91.5 and 87.7%. Area under the receiver operating curve showed that anti-CCP2 and anti-CCP3 had similar diagnostic performances. Diagnostic performance of the anti-CCP3 assay was comparable with the anti-CCP2 assay in Japanese patients with RA.
Literature
1.
go back to reference Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W et al (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10:1–229 Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W et al (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10:1–229
2.
go back to reference Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group et al (2004) Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50:1051–1065PubMedCrossRef Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group et al (2004) Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50:1051–1065PubMedCrossRef
3.
go back to reference Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D et al (2008) Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59:1467–1474PubMedCrossRef Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D et al (2008) Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59:1467–1474PubMedCrossRef
4.
go back to reference Sizova L (2008) Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br J Clin Pharmacol 66:173–178PubMedCrossRef Sizova L (2008) Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br J Clin Pharmacol 66:173–178PubMedCrossRef
5.
go back to reference Sheane BJ, Beddy P, O’Connor M, Miller S, Cunnane G (2009) Targeted ultrasound of the fifth metatarsophalangeal joint in an early inflammatory arthritis cohort. Arthritis Rheum 61:1004–1008PubMedCrossRef Sheane BJ, Beddy P, O’Connor M, Miller S, Cunnane G (2009) Targeted ultrasound of the fifth metatarsophalangeal joint in an early inflammatory arthritis cohort. Arthritis Rheum 61:1004–1008PubMedCrossRef
6.
go back to reference Lutteri L, Malaise M, Chapelle JP (2007) Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta 386:76–81PubMedCrossRef Lutteri L, Malaise M, Chapelle JP (2007) Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta 386:76–81PubMedCrossRef
7.
go back to reference Lee AN, Beck CE, Hall M (2008) Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: a review. Clin Lab Sci. 21:15–18PubMed Lee AN, Beck CE, Hall M (2008) Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: a review. Clin Lab Sci. 21:15–18PubMed
8.
go back to reference Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749PubMedCrossRef Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749PubMedCrossRef
9.
go back to reference Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386PubMedCrossRef Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386PubMedCrossRef
10.
go back to reference Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835PubMedCrossRef Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835PubMedCrossRef
11.
go back to reference Boyesen P, Hoff M, Odegard S, Haugeberg G, Syversen SW, Gaarder PI et al (2009) Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study. Arthritis Res Ther 11:R103PubMedCrossRef Boyesen P, Hoff M, Odegard S, Haugeberg G, Syversen SW, Gaarder PI et al (2009) Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study. Arthritis Res Ther 11:R103PubMedCrossRef
12.
go back to reference van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW et al (2009) Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60:2232–2241PubMedCrossRef van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW et al (2009) Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60:2232–2241PubMedCrossRef
13.
go back to reference Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095PubMedCrossRef Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095PubMedCrossRef
14.
go back to reference Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Karim Z et al (2009) Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum 60:1915–1922PubMedCrossRef Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Karim Z et al (2009) Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum 60:1915–1922PubMedCrossRef
15.
go back to reference Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ et al (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95:2672–2679PubMedCrossRef Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ et al (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95:2672–2679PubMedCrossRef
16.
go back to reference Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ (1979) Anti-keratin antibodies in rheumatoid arthritis. Br Med J 2:97–99PubMedCrossRef Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ (1979) Anti-keratin antibodies in rheumatoid arthritis. Br Med J 2:97–99PubMedCrossRef
17.
go back to reference Gan SQ, McBride OW, Idler WW, Markova N, Steinert PM (1990) Organization, structure, and polymorphisms of the human profilaggrin gene. Biochemistry 29:9432–9440PubMedCrossRef Gan SQ, McBride OW, Idler WW, Markova N, Steinert PM (1990) Organization, structure, and polymorphisms of the human profilaggrin gene. Biochemistry 29:9432–9440PubMedCrossRef
18.
go back to reference Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273–281PubMedCrossRef Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273–281PubMedCrossRef
19.
go back to reference Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089PubMedCrossRef Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089PubMedCrossRef
20.
go back to reference Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A et al (2006) Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 45:478–480CrossRef Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A et al (2006) Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 45:478–480CrossRef
21.
go back to reference Rojas-Serrano J, Burgos-Vargas R, Lino Pérez L, García García C, Moctezuma F, Vázquez-Mellado J (2009) Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Rheumatol 28:1135–1139PubMedCrossRef Rojas-Serrano J, Burgos-Vargas R, Lino Pérez L, García García C, Moctezuma F, Vázquez-Mellado J (2009) Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Rheumatol 28:1135–1139PubMedCrossRef
22.
go back to reference Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R (2001) Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47:1089–1093PubMed Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R (2001) Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47:1089–1093PubMed
23.
go back to reference dos Anjos LM, Pereira IA, d‘Orsi E, Seaman AP, Burlingame RW, Morato EF (2009) A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 28:153–158PubMedCrossRef dos Anjos LM, Pereira IA, d‘Orsi E, Seaman AP, Burlingame RW, Morato EF (2009) A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 28:153–158PubMedCrossRef
24.
go back to reference van Gaalen FA, Visser H, Huizinga TW (2005) A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 64:1510–1512PubMedCrossRef van Gaalen FA, Visser H, Huizinga TW (2005) A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 64:1510–1512PubMedCrossRef
25.
go back to reference Kitahara K, Takagi K, Kusunoki Y, Nishio S, Nozaki T, Inomata H et al (2008) Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Ann Rheum Dis 67:1059–1060PubMedCrossRef Kitahara K, Takagi K, Kusunoki Y, Nishio S, Nozaki T, Inomata H et al (2008) Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Ann Rheum Dis 67:1059–1060PubMedCrossRef
26.
go back to reference Matsui T, Shimada K, Ozawa N, Hayakawa H, Hagiwara F, Nakayama H et al (2006) Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol 33:2390–2397PubMed Matsui T, Shimada K, Ozawa N, Hayakawa H, Hagiwara F, Nakayama H et al (2006) Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol 33:2390–2397PubMed
27.
go back to reference Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S et al (2008) A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 27:77–83PubMedCrossRef Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S et al (2008) A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 27:77–83PubMedCrossRef
28.
go back to reference Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870–874PubMedCrossRef Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870–874PubMedCrossRef
29.
go back to reference Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084PubMedCrossRef Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084PubMedCrossRef
Metadata
Title
Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis
Authors
Kumi Shidara
Eisuke Inoue
Eiichi Tanaka
Daisuke Hoshi
Yohei Seto
Ayako Nakajima
Shigeki Momohara
Atsuo Taniguchi
Hisashi Yamanaka
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1336-2

Other articles of this Issue 5/2011

Rheumatology International 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.